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Abstract
OBJECTIVE: To investigate the effects of Yiqibush-
enhuoxue decoction on stable chronic obstructive
pulmonary disease (COPD) by observing its influ-
ences on patients' quality of life and airway inflam-
mation.
METHODS: Seventy patients with stable COPD
were randomly divided into a treatment group (n=
35) treated with Yiqibushenhuoxue decoction plus
Seretide and a control group (n=35) treated with
Seretide only. The dosage of Yiqibushenhuoxue de-
coction was 100 mL each time, twice a day, and the
dosage of Seretide was salmeterol 50 μg/flutica-
sone 250 μg twice a day. Both groups were treated
for 12 weeks. Before and after the treatment, St
George's respiratory disease questionnaire (SGRQ)
scores, forced expiratory volume, and forced expira-
tory volume in 1 second/forced vital capacity (FEV1/
FVC) were measured.
RESULTS: The SGRQ scores in both groups were sig-
nificantly lower than those before treatment (P<
0.05). After treatment, the total SGRQ scores and
each subscore in the treatment group were signifi-
cantly lower than those in the control group (P<
0.05). The percentage of the predicted FEV1% and
FEV1/FVC were higher in both groups, but no statis-
tical differences were detected from before to after
the treatment or between the two groups (P>0.05).
CONCLUSION: Yiqibushenhuoxue decoction could
significantly decrease the SGRQ scores in patients
with stable COPD, which suggests that it is able to
improve patient symptoms.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is de-
fined as "a preventable and treatable disease, which is
characterized by persistent airflow limitation that is
usually progressive and associated with an enhanced
chronic inflammatory response in the airways and the
lung to noxious particles or gases".1 The airway inflam-
mation is related to a variety of physiological and path-
ological processes such as tissue damage, airway remod-
eling, high mucus secretion, and a lack of elasticity,
and plays an important role in the pathogenesis of
COPD.2 At present, the treatment (including Western
Medicine and integrative medicine therapy) of acute
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exacerbations of COPD are somewhat effective. How-
ever, effective follow-up treatment during stable
COPD, and to prevent relapses are urgently needed.
Stable COPD treatment aims to alleviate symptoms,
reduce the frequency and severity of attacks, improve
pulmonary function, and improve the patients' quality
of life.3 While modern medicine is effective for stable
COPD, some limitations still exist, such as side effects
and limited long-term use. These side effects leave
COPD patients with a lack treatment options and ef-
fective herbs, which can lead to recurrent attacks and
further development of the disease. In this randomized
controlled clinical trial, we observed the influences of
Yiqibushenhuoxue decoction on the quality of life, pul-
monary function, and airway inflammation of COPD
patients, and compared them with those of convention-
al treatment.
MATERIALS ANDMETHODS
Demographics
Seventy outpatients of the Department of Respiratory
Medicine in the First Affiliated Hospital of Heilongji-
ang University of Chinese Medicine from February
2012 to June 2013, were divided into a treatment and
control group by means of random number table, with
35 patients in each. This study was approved by the
ethics committee of the First Affiliated Hospital of Hei-
longjiang University of Chinese Medicine. All patients
signed an informed consent form.
Diagnostic criteria
The diagnostic criteria for COPD was based on the
global strategy for the diagnosis, management, and pre-
vention of chronic obstructive pulmonary disease up-
dated in 2011.1 Clinical severity classification standard
was set according to the guidelines of diagnosis and
treatment of chronic obstructive pulmonary disease.3
The specific grading criteria are as follows: mild cases:
forced expiratory volume in 1 second/forced vital ca-
pacity (FEV1/FVC)<70%, FEV1% ≥80%, with or with-
out chronic cough, sputum symptoms; moderate cases:
FEV1/FVC<70%, 50%≤FEV1%<80%, with or without
chronic cough, sputum, dyspnea symptoms.
The diagnostic criteria for lung and kidney Qi deficien-
cy and blood stasis in terms of Traditional Chinese
Medicine (TCM) were based on the guidelines4 for the
TCM diagnosis and treatment of chronic obstructive
pulmonary disease. Patients with more than two of
1-3, more than two of 4-7, and more than one of 8-11
were considered to have lung and kidney Qi deficiency
and blood stasis. 1: wheezing or shortness of breath,
which is aggravated after activity; 2: lack of power or
sweating, which is aggravated when moving; 3: suscep-
tible to colds, and a serious attack by wind; 4: soreness
and weakness of the waist and knees; 5: tinnitus, dizzi-
ness, or edema of the face; 6: frequent urination, noctu-
ria, or cough urination; 7: pale tongue and white coat-
ed tongue, deep and thready pulse, or weak pulse; 8:
dark purple complexion; 9: cyanosis of the lips and
nails; 10: dark purple tongue, or tongue with petechia;
11: circuitous or coarse sublingual vein.
Inclusive criteria
This study recruited patients with COPD and lung
and kidney Qi deficiency and blood stasis. All patients
were classified as having mild or moderate disease that
was stable for more than half a month.
Exclusive criteria
Patients were excluded if they met any of the following
criteria: were definitely diagnosed of bronchial asthma;
had serious heart, liver, or kidney functional impair-
ment; were pregnant or currently lactating; or had an
allergic constitution or were allergic to any herbs used
in this study.
Rejected criteria
Patients were removed from the study if they met any
of the following criteria: they failed to use the pre-
scribed medication so that we were unable to judge the
curative effect; their data were not complete, which
could affect efficacy or safety judgments; or they did
not meet the inclusive criteria after inclusion.
Suspended and removal criteria
Patients were suspended and removed if they: could
not cooperate throughout the study; had serious ad-
verse reactions or serious complications; or had disease
exacerbations and needed to take active treatment mea-
sures.
Therapy
Both of the treatment and the control group were giv-
en Salmeterol Xinafoate and fluticasone propionate
powder for inhalation (Glaxo Smith Kline Plc, UK),
salmeterol 50 μg/fluticasone 250 μg, twice a day. In ad-
dition to the basic medication, patients in the treat-
ment group were also given an herbal decoction, which
was composed of: Dangshen (Radix Codonopsis) 20 g,
Huangqi (Radix Astragali Mongolici) 20 g, Wuweizi
(Fructus Schisandrae Chinensis) 15 g, Shudihuang (Ra-
dix Rehmanniae Praeparata) 15 g, Buguzhi (Fructus Pso-
raleae) 15 g, Yinyanghuo (Herba Epimedii Brevicornus)
15 g, Ziwan (Radix Asteris Tatarici) 15 g, Kuandong-
hua (Flos Farfarae) 15 g, Zisuzi (Fructus Perillae Ar-
gutae) 15 g, Banxia (Rhizoma Pinelliae) 10 g, Sumu (Lig-
num Sappan) 10 g, Shanzhuyu (Fructus Corni) 15 g,
Huangjing (Rhizoma Polygonati Sibirici) 15 g, and Gan-
cao (Radix Glycyrrhizae) 5 g. The above herbs were de-
cocted and concentrated to 200 mL juice. The dosage of
herbal decoction was 200 mL every day with 100 mL tak-
en orally in the morning and evening. The herbal de-
coction was prepared by the Pharmaceutical Factory of
the First Affiliated Hospital of Heilongjiang University
of Chinese Medicine. Both groups were treated for 12
weeks.
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Measurement
The measurement included St George's respiratory dis-
ease questionnaire (SGRQ).5 This questionnaire was di-
vided into three parts: respiratory symptoms, activity
ability, and impacts of the disease. There were 50
items in total to evaluate the patients' quality of life.
The higher the score is, the worse the health status of
the patient. Pulmonary function tests, FEV1/FVC and
FEV1% were tested and recorded on the first visit and
again after the 12 week treatment.
Data analysis
Data were analyzed with SPSS software version 17.0
(SPSS Inc., Chicago, IL, USA). The data were repre-
sented as ( xˉ ± s). t-test was used to compare data be-
tween groups. P<0.05 was considered significant.
RESULTS
Comparison of the general statistics before treatment
Seventy patients recuited in this study were randomly
divided into a treatment and control group with 35 pa-
tients in each. All the subjects recuited were at the age
of 48-74 years old. The illness course of the treatment
group was 2-10 years, while that of the control group
was 2-12 years. After the trial, all the patients who
completed the trial in two groups (treatment group
32 cases, control group 33 cases) conducted a fol-
low-up, and showed good clinical effect with no adw-
erse reactions. The flow diagram of the trial is shown
in Figure 1.
There were no significant differences in gender, age,
course of disease, or severity level between two groups
before treatment (P>0.05) as shown in Table 1.
Comparison of SGRQ scores before and after
treatment
There were no statistical significances in the total
SGRQ score and its three parts between two groups be-
fore treatment (P>0.05). The SGRQ scores after treat-
ment in both groups were significantly lower than
those before treatment (P<0.05). There was a statistical
difference between the two groups in the total scores,
the respiratory symptom score, activity ability score,
and impacts of the disease score after treatment (P<
0.05) (Table 2).
Comparison of FEV1% and FEV1/FVC before and
after treatment
There were no statistical differences in FEV1% and
FEV1/FVC between two groups before treatment (P>
0.05). The FEV1% and FEV1/FVC after treatment
were both higher in the two groups compared with be-
fore treatment. However, this increase was not statisti-
cally significant (P>0.05). There were no statistical dif-
ferences between two groups in FEV1% and FEV1/
FVC after treatment (P>0.05) (Table 3).
DISCUSSION
COPD is a common respiratory disease. Many pa-
tients' clinical symptoms are not well controlled as the
disease has recurrent attacks, and the pulmonary func-
tion and quality of life of patients tend to decline.
Many patients eventually succumb to diseases related
to the lung. Treatment during the stable period aims at
reducing symptoms and future risks, and can effective-
ly reduce the frequency of acute attacks. The etiology
and pathogenesis of COPD are very complex. Li et al 6
summarized the pathogenesis of COPD as "weakened
Figure 1 Flow diagram of the trial
COPD: chronic obstructive pulmonary disease.
Assessed for eligibility
(n=70)
Enrolled and
randomized (n=70)
Treatment group
(n=35)
Control
group (n=35)
Completed 3 month
assessment (n=32)
Lost to follow up (n=2)
COPD exacerbation (n=1)
Completed 3 month
assessment (n=31)
Lost to follow up (n=1)
COPD exacerbation (n=1)
Analysis (n=32) Analysis (n=31)
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body resistance and accumulated pathogens." Weak-
ened body resistance refers to the deficiency of lung,
spleen, and kidney. In this weakened body resistance,
pulmonary deficiency is the beginning, kidney deficien-
cy is the base, and Qi deficiency is the origin, while ac-
cumulated pathogens include phlegm and blood stasis.
Chronic illness caused by accumulated pathogens is
very difficult to treat and damages healthy Qi, to the
extent that healthy Qi becomes more deficient and
pathogens further accumulate. At the beginning of the
disease, the dispersing and descending function of the
lung is impaired because of exogenous pathogens.
Then, lung injury caused by chronic cough leads to
pulmonary Qi deficiency. As the disease progresses,
phlegm is produced and injures the lung because the
spleen is so deficient that it cannot transport and trans-
form water and fluid. Furthermore, chronic illness
damages the kidney so that kidney fails to receive Qi.
This dysfunction of the kidney leads to additional
cough and difficulty breathing. Healthy Qi becomes
deficient because of chronic illness so its promoting
and warming function declines. Humor clusters into
phlegm and blood stops running, which turns into sta-
sis. Li et al 7 found, by studying the distribution of pat-
terns in 209 COPD patients, that the phlegm was the
most common excess pattern, and blood-stasis was
second.
The treatment of COPD with TCM has significant
clinical effects, especially in patients with stable
COPD. Relevant clinical and basic studies having re-
ceived increasing attention, and having made some
progress.8 According to the pathological features of sta-
ble COPD, we established the treatment principle of
"benefiting the lung and kidney, invigorating the circu-
lation and resolving phlegm." In this decoction, the
monarch herbs, Dangshen (Radix Codonopsis) replen-
ishes Qi and Huangqi (Radix Astragali Mongolici) toni-
fies the lung, while securing the exterior, enhancing
the efficacy of the total complement of lung Qi. Wu-
weizi (Fructus Schisandrae Chinensis) can converge the
lung and relieve cough, preventing lung Qi from fur-
ther consumption, and can also nourish kidney yin.
Group
Treatment
Control
n
32
33
Time
Before treatment
After treatment
Before treatment
After treatment
FEV1%
69±12a
70±12bc
68±12
70±12c
FEV1/FVC
61±4a
63±4bc
61±4
63±4c
Table 3 Comparison of FEV1% and FEV1/FVC ( xˉ ±s)
Notes: the treatment group was treated with Yiqibushenhuoxue decoction (100 mL each time, twice a day) and Seretide (one inhale salme-
terol 50 μg/fluticasone 250 μg each time, twice a day); the control group was treated with Seretide (one inhale salmeterol 50 μg/fluticasone
250 μg each time, twice a day). FEV1%: the percentage of the predicted forced expiratory volume in 1 second; FEV1/FVC: forced expiratory
volume in 1 second/forced vital capacity. aP>0.05, compared with the control group before treatment; bP>0.05, compared with the control
group after treatment; cP>0.05, compared with before treatment.
Group
Treatment
Control
n
32
33
Time
Before treatment
After treatment
Before treatment
After treatment
Respiratory symptom
45±12a
30±10bc
45±11
37±8c
Activity ability
31±6a
19±4bc
30±6
22±5c
The impacts of disease
21±6a
13±6bc
23±6
16±6c
Total score
28±9a
20±8bc
29±9
25±9c
Notes: the treatment group was treated with Yiqibushenhuoxue decoction (100 mL each time, twice a day) and Seretide (one inhale salme-
terol 50 μg/fluticasone 250 μg each time, twice a day); the control group was treated with Seretide (one inhale salmeterol 50 μg/fluticasone
250 μg each time, twice a day). SGRQ: George's respiratory disease questionnaire. aP>0.05, compared with the control group before treat-
ment; bP<0.05, compared with the control group after treatment; cP>0.05, compared with itself before treatment.
Table 2 Comparison of SGRQ scores ( xˉ ±s)
Group
Treatment
Control
P value
n
32
33
-
Gender
Male
17
17
0.897
Female
15
16
Age (years)
63.0±6.1
64.8±6.4
0.230
Course of disease
(years)
5.6±2.8
5.1±2.6
0.482
Severity level
Mild
12
10
0.540
Moderate
20
23
Table 1 Comparison of the general situation before treatment
Notes: the treatment group was treated with Yiqibushenhuoxue decoction (100 mL each time, twice a day) and Seretide (one inhale salme-
terol 50 μg/fluticasone 250 μg each time, twice a day); the control group was treated with Seretide (one inhale salmeterol 50 μg/fluticasone
250 μg each time, twice a day).
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Shudi can tonify the kidney to receive Qi and relieve
breathing. Buguzhi (Fructus Psoraleae) warms the kid-
ney to receive Qi. Huangjing (Rhizoma Polygonati Si-
birici) nourishes Yin and moistens the lung, nourishes
the kidney, strengthens the essence, and increases in ef-
ficacy with Jin and Shui. Kuandonghua (Flos Farfarae)
and Ziyuan can moisten the lung, relieve cough and re-
duce phlegm. Zisuzi (Fructus Perillae Argutae) can de-
scend the adverse-rising Qi, resolve phlegm, and relieve
cough and breathing. Banxia (Rhizoma Pinelliae) can
remove dampness to reduce phlegm. Each of these
herbs are ministerial herbs. The adjuvant herbs are
Sumu (Lignum Sappan), which is used for promoting
blood circulation and removing blood stasis, and Shan-
zhuyu, for nourishing kidney Yin. Gancao (Radix Glyc-
yrrhizae), the conductant drug, can reconcile the vari-
ous herbs, relieve cough, resolve phlegm. Various herbs
used in the decoction can benefit the lung and kidney,
invigorating the circulation, and resolving phlegm.
Modern pharmacology studies have shown that Dang-
shen has various physiological functions, including an-
ti-inflammation, immune regulation, and anti-hypox-
ic.9,10 Moreover, astragaloside Ⅳ, the principal active
component of Huangqi (Radix Astragali Mongolici),
can effectively restrain the chronic asthma induced by
ovalbumin, decrease airway sensitivity, alleviate airway
fibrosis, remove thickened smooth muscle, and inhibit
goblet cell hyperplasia. The combined use of Dangsh-
en (Radix Codonopsis) and Huangqi (Radix Astragali
Mongolici) can amplify their range of application and
increase efficacy.11 Yinyanghuo (Herba Epimedii Brevi-
cornus) can correct axis disorders, promote the anti-in-
flammatory and immune capacity of the body, and re-
sist the fibrosis and remodeling of the airway.12 Sumu
(Lignum Sappan) can optimize the immune response at
the cellular and molecular level, and has anti-inflamma-
tory, microcirculatory, and antioxidative properties.13
We showed that Yiqibushenhuoxue decoction could
significantly lower the GRDQ scores of patients with
stable COPD. However, there were no statistical differ-
ences between the two groups in FEV1% and FEV1/
FVC before and after treatment. This implies that Yiqi-
bushenhuoxue decoction could significantly improve a
patients' symptoms as measured by the SGRQ scores
only. Although the FEV1% and FEV1/FVC improved,
this change was not statistically significant compared
with before treatment, possibly because of the study
was too short. Whether Yiqibushenhuoxue decoction
can change the trend of lung function decline in pa-
tients with COPD should be studied further. Because
of a relatively small study sample size and short obser-
vational time, studies with large samples and longer du-
rations should be conducted to further substantiate our
findings.
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